Xu, X., Tang, L., Piao, X., Zhan, S., Chen, Y., Feng, P. (2026). Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. PLoS ONE. https://doi.org/10.1371/journal.pone.0349044